Developing a quality evaluation indicator system for lung cancer diagnosis and treatment: a modified Delphi method study Authors: Liming Shi, Kailun Fei, Meicen Liu, Chengcheng Zhou, Juan Yang, Jincheng Yang, Jie Wang, Zhijie Wang, Wenjing Yang Published: 2026 ABSTRACT ObjectiveTo establish a quality evaluation index system for the diagnosis and treatment of lung cancer.MethodThe Donabedian health assessment model and Delphi method were used to construct an indicator system, and the Analytic Hierarchy Process was used to determine the weights of each level of indicators.ResultThe final indicator system constructed includes 3 primary indicators: structure, process and outcome, 15 secondary indicators, and 55 tertiary indicators. Structural indicators include staff, regulations, and facilities; Process indicators include diagnosis, multidisciplinary team (MDT), Neoadjuvant therapy, surgical treatment, adjuvant treatment, radiation therapy, systemic therapy, patient follow-up and patient-centered; Outcome indicators include effectiveness, safety and timeliness. Of the two rounds of Delphi experts consulting, the Expert Enthusiasm Coefficient were respectively 100.0% and 96.15%, the Expert Authority Coefficient were respectively 0.818 and 0.825, and Expert Coordination Coefficient was between 0.476 ~ 0.748.ConclusionThe quality evaluation indicator system of lung cancer has high credibility and can be used as a tool for evaluating the quality of lung cancer care.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12885-026-15938-y. Introduction According to the latest data released by the International Agency for Research on Cancer (IARC) in the 2022 Global Cancer Statistics (GLOBCAN2022), there were approximately 20 million new cancer cases worldwide in 2022, with lung cancer being the most common, accounting for 12.4% of new cases. In China, Lung cancer is the most prevalent and deadly cancer, with a standardized incidence rate of 40.78 per 100,000, accounting for 42.8% of the global lung cancer new cases. The standardized mortality rate is 26.66 per 100,000, representing 40.3% of the global lung cancer deaths. The situation of cancer prevention and control in China is severe, with cancer diagnosis and treatment imposing a dual burden on patients both physically and financially [1–2]. The Chinese government places great emphasis on cancer prevention and treatment and have released a series of policies since 2009. In 2020, the National Health Commission issued the Notice on Further Strengthening the Quality Management and Control of Single Disease Diagnosis and Treatment, proposing the establishment of a quality control and evaluation system based on the entire process of disease diagnosis and treatment for medical quality management [3]. Medical quality evaluation serves as both a tool for external quality verification to ensure safety and quality, and as an internal review tool for continuous quality improvement within institutions. By identifying key problems, the medical care quality can be enhanced. The National Cancer Center (NCC) has undertaken a series of initiatives for single-disease quality control, including organizing expert committees for various cancer types, developing quality control indicators, conducting single disease standardized diagnosis and treatment and quality control pilot project. However, a comprehensive quality evaluation system has not yet been established. This study aims to construct a comprehensive quality evaluation system for lung cancer diagnosis and treatment by employing scientific research methods. Method Research framework Donabedian healthcare evaluation model The Donabedian Healthcare Quality Evaluation Model, proposed by American healthcare quality scholar Avedis Donabedian, decomposes healthcare quality into three interrelated dimensions: Structure, Process, and Outcome, providing an operational analytical framework for the systematic assessment of healthcare service quality [4–6]. The Structure dimension focuses on the basic conditions for providing healthcare services, covering “static elements” such as the hardware facilities of medical institutions and organizational management systems. These elements are the prerequisites for ensuring healthcare quality and directly affect the standardization of service processes and final outcomes. The Process dimension refers to the specific implementation links of healthcare services, including “dynamic behaviors” such as diagnostic procedures and the formulation and implementation of treatment plans. Process quality is the core link connecting structure and outcome, and its standardization directly determines the quality of outcomes. The Outcome dimension measures the final effectiveness of healthcare services, including clinical indicators and patient-level outcomes. In this study, the three dimensions of the Donabedian model are directly incorporated into the design of primary indicators for the lung cancer diagnosis and treatment quality evaluation index system. Specifically: the Structure dimension corresponds to the “basic guarantee capacity for lung cancer diagnosis and treatment”, such as evaluating whether medical institutions have quality management systems; the Process dimension focuses on the “standardized procedures for lung cancer diagnosis and treatment”, covering the full-process operation standards from screening, diagnosis to treatment and follow-up; the Outcome dimension points to the “actual effectiveness of lung cancer diagnosis and treatment”. Through this framework, the study constructs an evaluation system from the full-chain perspective of “input-implementation-output”, ensuring that the evaluation of lung cancer diagnosis and treatment quality is both comprehensive and logically consistent. IOM quality evaluation framework In 2001, the Institute of Medicine (IOM) proposed six dimensions of healthcare quality in its landmark report Crossing the Quality Chasm: A New Health System for the 21st Century, namely Safety, Effectiveness, Patient-centeredness, Timeliness, Efficiency, and Equity. This framework was later adopted by the World Health Organization (WHO) and became the core guiding principle for global healthcare quality improvement [7–8]. Safety emphasizes avoiding preventable harm caused by medical behaviors, such as reducing medication errors or nosocomial infections; Effectiveness requires healthcare services to be based on evidence-based medical evidence, providing only interventions beneficial to patients and avoiding ineffective treatments; Patient-centeredness focuses on patients’ individual needs and preferences, ensuring patients’ right to know and participate in diagnosis and treatment; Timeliness aims to shorten the time interval from patients’ need generation to service acquisition, such as reducing the waiting time for diagnosis; Efficiency focuses on the rational use of resources, reducing unnecessary medical costs and avoiding waste; Equity emphasizes that healthcare services should not be affected by factors such as patients’ race, economic status, and region, ensuring equal access. In this study, the IOM framework mainly provides a basis for the refinement of secondary and tertiary indicators. For example, in the “Outcome indicators”, combined with the “Safety” dimension, indicators such as “severe complications of tumor patients after surgery” are set; based on the “Effectiveness” dimension, indicators such as “evaluation results of systemic treatment efficacy” are included; with reference to the “Patient-centered” dimension, indicators “survey on the diagnosis and treatment experience of tumor patients” are set. In combination with the “Timeliness” dimension, the indicator “time from initial diagnosis to first treatment” is set. Research process Literature review The construction of the initial indicators in this study was derived from the following sources: (1) Academic literature searches in both Chinese and English databases, including CNKI, Wanfang Database, PubMed, and Web of Science, using keywords such as “tumor/cancer/lung cancer”, “quality assessment/quality evaluation”, and “quality indicators/quality measures/quality metrics”; (2) Searches of international websites, including organizations engaged in quality control and improvement projects in the United States, such as the National Cancer Institute (NCI), the Surveillance, Epidemiology, and End Results (SEER) Program database, the National Cancer Database (NCDB), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN); (3) Searches of domestic policy documents, including the *Chinese Lung Cancer Diagnosis and Treatment Quality Control Indicators (2022 Version)* and the National Performance Evaluation Indicators for Tertiary Public Hospitals. These materials were integrated to form the primary indicator pool for the lung cancer diagnosis and treatment quality evaluation system. Expert interviews Three experts with extensive experience in clinical practice and quality management were invited to discuss the content and feasibility of the preliminary indicator system. Both clinical and quality management experts acknowledged the comprehensiveness and objectivity of these indicators. Meanwhile, two clinical experts, taking into account domestic clinical realities and data accessibility, reclassified the 5-year survival rate from an outcome indicator to a process indicator. This adjustment aims to strengthen long-term follow-up of patients across medical institutions. Additionally, due to the challenges in collecting and analyzing cost data, economic indicators were excluded from this study. Modified Delphi method A modified Delphi method was used to solicit opinions and suggestions from experts in the field of oncology. The selection criteria for experts included: (1) approximately 10 members of the Lung Cancer Single-Disease Quality Control Expert Committee of NCC; (2) approximately 10 clinical experts and administrators from the first batch of lung cancer standardized diagnosis and treatment quality control pilots; and (3) approximately 5 experts in medical quality management. The experts were required to hold associate senior titles or higher, have a strong interest and extensive experience in oncology diagnosis and treatment quality control, and be able to provide comprehensive and objective opinions and suggestions. The selection of experts also considered regional representation from eastern, central, and western China [9–10]. A questionnaire was designed based on the preliminary lung cancer quality evaluation indicator system, and the Delphi method was conducted in two rounds. Experts scored the importance, familiarity, and judgment basis of the indicators and provided suggestions for revision.The English versions of the two rounds of Delphi questionnaires are available in the supplementary files (Supplementary Files 1 and 2).Notably, the judgment basis scoring explicitly incorporated four dimensions with respective weights: Practical experience (40%), Theoretical analysis (30%), Literature knowledge (20%), and Intuition (10%). These weights were assigned to reflect their relative contribution to expert judgment—prioritizing empirical and theoretical foundations while acknowledging the supplementary role of academic literature and professional intuition. Practical experience refers to hands-on clinical or management insights accumulated through professional practice; Theoretical analysis involves evaluation based on established medical theories and quality management frameworks; Literature knowledge draws on evidence from academic research, guidelines, and consensus statements; Intuition represents experts’ implicit professional judgment. The inclusion criteria for indicators were: (1) an arithmetic mean score of importance ≥ 7.0; and (2) a coefficient of variation for importance ≤ 0.20. Analytic Hierarchy Process (AHP) The weights of primary indicators were determined using the expert direct weighting method, while the weights of secondary and tertiary indicators were calculated using the AHP, the relative importance of all indicators was assigned using Saaty’s 1–9 scale. Pairwise comparison matrices are construct for weight calculation, the consistency ratio (CR) of the matrix was tested. The combined weight of a tertiary indicator is the product of the weights of its associated primary, secondary, and tertiary indicators [11–12]. Statistical analysis Microsoft Excel 2019 was used to calculate the expert Enthusiasm coefficient, authority coefficient, and coordination coefficient, with a significance level of 0.05. The expert Enthusiasm coefficient was measured by the effective response rate and suggestion given. The expert authority coefficient (Cr) was calculated as the arithmetic mean of the expert familiarity coefficient (Cs) and the judgment basis coefficient (Ca). Expert familiarity was measured using a Likert 5-point scale, ranging from “not familiar” to “very familiar,” with scores of 0.2, 0.4, 0.6, 0.8, and 1, respectively. The judgment basis coefficient was calculated based on the expert judgment criteria in Table 1. A Cr ≥ 0.7 was considered reliable. Kendall’s W coefficient was used to measure the coordination of expert opinions, with values ranging from 0 to 1, higher values indicated greater coordination among experts. Scientific Platform Serving for Statistics Professional (SPSSPRO)software v28.0 was used to determine the weights of the indicators using AHP. Table 1Expert judgment basis criteriaCategoryImpact level for expert judgmentHighMediumLowPractical experience0.400.200Theoretical analysis0.300.150Literature knowledge0.200.100Intuition0.100.050 Table 1Expert judgment basis criteriaCategoryImpact level for expert judgmentHighMediumLowPractical experience0.400.200Theoretical analysis0.300.150Literature knowledge0.200.100Intuition0.100.050 Expert judgment basis criteria Result Expert information and enthusiasm coefficient A total of 26 experts were selected for the two rounds of the Delphi method. The basic information of the experts is shown in Table 2. In the first round, 26 questionnaires were distributed and 26 were returned, with a 100% effective response rate. In the second round, 26 questionnaires were distributed and 25 were returned, with a 96.15% effective response rate, indicating a high level of enthusiasm among the experts. Four experts provided question and suggestion in the first round, and one provided question in the second round. Table 2Expert information(n=26)CategoryExpert NumberProportion(%)Education Doctor and above1557.69% Master623.08% Bachelor519.23%Professional title Senior2284.62% Associate senior415.38%Years of work ≥40519.23% 30~391038.46% 20~29311.54% 10~19830.77%Research area Clinical2076.92% Medical technology27.69% Management415.38%Work time direct to patients ≥50%1765.38% 10%~49%726.92% <10%27.70% Table 2Expert information(n=26)CategoryExpert NumberProportion(%)Education Doctor and above1557.69% Master623.08% Bachelor519.23%Professional title Senior2284.62% Associate senior415.38%Years of work ≥40519.23% 30~391038.46% 20~29311.54% 10~19830.77%Research area Clinical2076.92% Medical technology27.69% Management415.38%Work time direct to patients ≥50%1765.38% 10%~49%726.92% <10%27.70% Expert information(n=26) Expert authority coefficient and coordination coefficient In the first round, the Ca, Cs and Cr values were 0.946, 0.690, and 0.818, respectively, indicating reliable and authoritative results. The Kendall’s W coefficients for the primary, secondary, and tertiary indicators in the first round were respectively 0.748, 0.498, and 0.510, with statistically significant results (P < 0.05). In the second round, the Ca, Cs, and Cr values were respectively 0.942, 0.708, and 0.825 and the Kendall’s W coefficient for the tertiary indicators was 0.476, with statistically significant results (P < 0.05), indicating good coordination among the experts. Indicator screening results In both rounds of the Delphi method, all indicators met the criteria of an arithmetic mean score of importance ≥ 7.0 and a coefficient of variation for importance ≤ 0.20. The main feedback from the first round included suggestions to clarify the requirements for pulmonary nodules in the clinical TNM staging examination strategies before initial treatment and the standardization of lymph node dissection in lung cancer surgery, and indicator nutrition assessment before treatment was suggested. After discussion, a preoperative nutritional assessment indicator was added in the second round. No additional indicators were proposed or removed in the second round. The final indicator system included 3 primary indicators, 15 secondary indicators, and 55 tertiary indicators. Weight setting The results of the second round of the Delphi method were entered into SPSSPRO software to construct pairwise comparison matrices for weight calculation. The combined weights of the tertiary indicators were calculated using the product method. The CR values of all levels of indicators were < 0.1, passing the consistency test. The final lung cancer diagnosis and treatment quality evaluation framework (Fig. 1) and the three-level indicator system with weights (Table 3) were established. Fig. 1Lung cancer diagnosis and treatment quality evaluation framework Lung cancer diagnosis and treatment quality evaluation framework Table 3Lung cancer diagnosis and treatment quality evaluation indicator and weightPrimary indicatorSecondary indicatorTertiary indicatorComprehensive weight1. Structure (0.250)1.1 Staff (0.333)1.1.1 Two-level work team of quality control (hospital and department)0.0211.1.2 Clinician educational certification0.0211.1.3 Clinical pharmacist of Oncology0.0211.1.4 Nurse educational certification0.0211.2 Regulation (0.333)1.2.1 Quality control related regulations0.0211.2.2 Functional department quality audit0.0211.2.3 Clinical department quality self-examination0.0211.2.4 Quality related training0.0211.3 Facilities (0.333)1.3.1 Molecular Pathology Quality Certification0.0832. Process (0.500)2.1 Diagnosis (0.138)2.1.1 Pathological diagnosis0.0142.1.2 Histological subtype diagnosis0.0142.1.3 Molecular type diagnosis0.0142.1.4 Clinical TNM stage diagnosis0.0282.2 MDT(0.113)2.2.1 Multidisciplinary discussion0.0192.2.2 Appropriate multidisciplinary treatment strategy0.0192.2.3 Execution of multidisciplinary treatment strategy0.0192.3 Neoadjuvant therapy (0.071)2.3.1 Complete and standardized neoadjuvant therapy plan0.0072.3.2 Appropriate neoadjuvant therapy plan0.0072.3.3 Clinical TNM staging after neoadjuvant therapy0.0072.3.4 pathological staging after neoadjuvant therapy0.0072.3.5 pathological remission evaluation0.0072.4 Surgical therapy (0.138)2.4.1Standardized record of surgical plan0.0042.4.2 Appropriate surgical regimen0.0092.4.3 Preoperative nutritional risk screening0.0042.4.4 Preoperative VTE risk assessment0.0042.4.5 Preoperative bleeding risk assessment0.0042.4.6 Complete and standardized surgical records0.0092.4.7 lymph node dissection performed during lung cancer resection surgery0.0092.4.8 Sufficient lymph node dissection (sampling)0.0092.4.9 Complete and standardized pathological report0.0092.4.10 Postoperative pTN staging0.0092.5 Adjuvant therapy (0.138)2.5.1 Complete and standardized adjuvant therapy0.0372.5.2 Sufficient adjuvant treatment cycle0.0022.6 Radiotherapy (0.138)2.6.1 Complete and standardized radiotherapy plan0.0142.6.2 Appropriate radiotherapy regimen0.0142.6.3 Standardized radiotherapy record0.0142.6.4 Radiation Dose Completion0.0142.6.5 Radiotherapy efficacy evaluation implementation0.0142.7 Systematic therapy (0.138)2.7.1 Complete and standardized systemic therapy plan0.0152.7.2 Complete systemic therapy orders/prescriptions0.0082.7.3 Appropriate systematic regimen0.0152.7.4 Physical score before chemotherapy0.0082.7.5 Pain assessment before chemotherapy0.0082.7.6 Toxicity assessment before chemotherapy0.0082.7.7 Systematic therapy efficacy evaluation implementation0.0082.8 Patient follow-up (0.077)2.8.1 5 year follow-up after treatment0.0392.9 Patient-centered (0.049)2.9.1 Patient experience survey0.0253. Outcome (0.250)3.1 Effectiveness (0.400)3.1.1 Result of systematic therapy efficacy evaluation0.0503.1.2 Result of radiotherapy efficacy evaluation0.0253.1.3 R0 surgical resection0.0253.2 Safety (0.400)3.2.1 In-hospital death of patients undergoing elective surgery0.0333.2.2 Occurrence of surgical serious complications0.0333.2.3 Serious adverse reactions of anti-tumor drugs0.0173.2.4 Serious adverse reactions of radiotherapy0.0173.3 Timeliness (0.200)3.3.1 Time from first diagnosis to first treatment0.050 Table 3Lung cancer diagnosis and treatment quality evaluation indicator and weightPrimary indicatorSecondary indicatorTertiary indicatorComprehensive weight1. Structure (0.250)1.1 Staff (0.333)1.1.1 Two-level work team of quality control (hospital and department)0.0211.1.2 Clinician educational certification0.0211.1.3 Clinical pharmacist of Oncology0.0211.1.4 Nurse educational certification0.0211.2 Regulation (0.333)1.2.1 Quality control related regulations0.0211.2.2 Functional department quality audit0.0211.2.3 Clinical department quality self-examination0.0211.2.4 Quality related training0.0211.3 Facilities (0.333)1.3.1 Molecular Pathology Quality Certification0.0832. Process (0.500)2.1 Diagnosis (0.138)2.1.1 Pathological diagnosis0.0142.1.2 Histological subtype diagnosis0.0142.1.3 Molecular type diagnosis0.0142.1.4 Clinical TNM stage diagnosis0.0282.2 MDT(0.113)2.2.1 Multidisciplinary discussion0.0192.2.2 Appropriate multidisciplinary treatment strategy0.0192.2.3 Execution of multidisciplinary treatment strategy0.0192.3 Neoadjuvant therapy (0.071)2.3.1 Complete and standardized neoadjuvant therapy plan0.0072.3.2 Appropriate neoadjuvant therapy plan0.0072.3.3 Clinical TNM staging after neoadjuvant therapy0.0072.3.4 pathological staging after neoadjuvant therapy0.0072.3.5 pathological remission evaluation0.0072.4 Surgical therapy (0.138)2.4.1Standardized record of surgical plan0.0042.4.2 Appropriate surgical regimen0.0092.4.3 Preoperative nutritional risk screening0.0042.4.4 Preoperative VTE risk assessment0.0042.4.5 Preoperative bleeding risk assessment0.0042.4.6 Complete and standardized surgical records0.0092.4.7 lymph node dissection performed during lung cancer resection surgery0.0092.4.8 Sufficient lymph node dissection (sampling)0.0092.4.9 Complete and standardized pathological report0.0092.4.10 Postoperative pTN staging0.0092.5 Adjuvant therapy (0.138)2.5.1 Complete and standardized adjuvant therapy0.0372.5.2 Sufficient adjuvant treatment cycle0.0022.6 Radiotherapy (0.138)2.6.1 Complete and standardized radiotherapy plan0.0142.6.2 Appropriate radiotherapy regimen0.0142.6.3 Standardized radiotherapy record0.0142.6.4 Radiation Dose Completion0.0142.6.5 Radiotherapy efficacy evaluation implementation0.0142.7 Systematic therapy (0.138)2.7.1 Complete and standardized systemic therapy plan0.0152.7.2 Complete systemic therapy orders/prescriptions0.0082.7.3 Appropriate systematic regimen0.0152.7.4 Physical score before chemotherapy0.0082.7.5 Pain assessment before chemotherapy0.0082.7.6 Toxicity assessment before chemotherapy0.0082.7.7 Systematic therapy efficacy evaluation implementation0.0082.8 Patient follow-up (0.077)2.8.1 5 year follow-up after treatment0.0392.9 Patient-centered (0.049)2.9.1 Patient experience survey0.0253. Outcome (0.250)3.1 Effectiveness (0.400)3.1.1 Result of systematic therapy efficacy evaluation0.0503.1.2 Result of radiotherapy efficacy evaluation0.0253.1.3 R0 surgical resection0.0253.2 Safety (0.400)3.2.1 In-hospital death of patients undergoing elective surgery0.0333.2.2 Occurrence of surgical serious complications0.0333.2.3 Serious adverse reactions of anti-tumor drugs0.0173.2.4 Serious adverse reactions of radiotherapy0.0173.3 Timeliness (0.200)3.3.1 Time from first diagnosis to first treatment0.050 Lung cancer diagnosis and treatment quality evaluation indicator and weight Discussion Theoretical and practical implications of the indicator system The lung cancer diagnosis and treatment quality evaluation system constructed in this study, comprising 3 primary indicators, 15 secondary indicators, and 55 tertiary indicators, fills the gap in comprehensive quality assessment tools for lung cancer care. Grounded in the Donabedian model and IOM framework, the system integrates three dimensions: structural guarantees, process standardization, and outcome effectiveness, reflecting a holistic understanding of healthcare quality, by covering the full-cycle management of lung cancer from diagnosis and treatment to follow-up, this indicator system will play a pivotal role in promoting standardized clinical practice for lung cancer. Structural indicators, accounting for 25% of the total weight, focus on foundational elements such as the professional qualifications of medical teams, institutional regulations, and molecular pathology capabilities, addressing the “input” conditions necessary for high-quality care. For instance, indicators like the deployment of oncology clinical pharmacists (comprehensive weight: 0.021) and nurse certification requirements (0.021) ensure the establishment of a multidisciplinary professional support system, laying the groundwork for standardized diagnosis and treatment. Notably, molecular pathology quality certification (0.083) carries the highest weight among structural indicators, underscoring the central role of precise pathological diagnosis in guiding targeted therapy—a cornerstone of modern lung cancer management. Process indicators, comprising 50% of the total weight, form the core of the system, covering the entire continuum from diagnosis to follow-up. The high weight of diagnostic indicators (0.138) confirms their role as the “gateway” to effective treatment: clinical TNM staging (0.028) directly determine treatment strategies, with evidence showing that accurate staging reduces the rate of inappropriate treatment [13–14]. Molecular type diagnosis (0.014) is of great significance for the selection of new anti-tumor drugs. Surgical therapy (0.138), radiotherapy (0.138) and systematic therapy (0.138) also carry significant weight, this reflects the significance of treatment in clinical practice. It is worth noting that the weight of multidisciplinary team (MDT) indicators (0.113) is relatively lower compared to those of diagnostic and treatment process indicators. However, MDT plays a crucial role as an “enabling mechanism”. It provides support for diagnosis and treatment regimens selection, serving as a quality-driven factor throughout the entire process. Its implementation can still improve adherence to clinical guidelines and is of vital significance for patients’ prognosis [15]. Outcome indicators (25%) focus on effectiveness, safety, and timeliness. Key metrics include systemic treatment efficacy (0.050) and the time from initial diagnosis to first treatment (0.050), which reflect both short-term treatment outcomes and patient concerns about delays in care—aligning with the “timeliness” and “effectiveness” dimensions of the IOM framework. The inclusion of in-hospital mortality (0.033) and severe surgical complications (0.033) underscores patient safety as a non-negotiable quality benchmark. Comparison with existing research and alignment with policies This system advances existing quality assessment frameworks by integrating international consensus with domestic realities. Unlike international framework that emphasize 5-year survival as outcome, this study classifies 5-year follow-up as a process indicator (0.039)—a pragmatic adjustment given challenges in collecting medical institutions survival data. This shift encourages standardized long-term follow-up, indirectly laying the groundwork for improving survival outcomes. The system also responds to China’s policy directives, such as the National Health Commission’s call for full-cycle quality control. By incorporating preoperative nutritional assessment (second round added) and patient experience surveys (0.025), it addresses gaps in previous guidelines, which often overlooked supportive care and patient perspectives. These additions align with the global trend toward patient-centered care, as highlighted in the IOM framework. Limitations While the lung cancer diagnosis and treatment quality indicator system developed in this study demonstrates high scientific rigor and practical value, it is not without limitations. First, despite the adoption of the Delphi method to strengthen expert consensus, some valuable indicators were modified or excluded due to considerations of clinical practicability and data availability. These indicators warrant further supplementation and refinement in future research. Second, this study may require regional testing. Given the limited scope of the current research, such validation efforts should be conducted in subsequent studies to facilitate further optimization of the indicator system. Conclusion The quality evaluation indicator system for lung cancer diagnosis and treatment constructed in this study includes 3 primary indicators, 15 secondary indicators, and 55 tertiary indicators., focusing on early diagnosis of lung cancer, standardized treatment, and full-process patient management, aiming to systematically improve the overall quality of lung cancer diagnosis and treatment. The study adopted the Delphi method to conduct multiple rounds of expert consultation and demonstration, ensuring that the indicator system has practical guiding value. It deeply integrates the three dimensions of structure, process, and outcome in the Donabedian model, emphasis is placed on the whole-process management of lung cancer diagnosis and treatment, thus forming an evaluation framework with rigorous logic and clear hierarchy. Meanwhile, this study innovatively built a full-cycle quality supervision mechanism covering links such as postoperative follow-up and patient experience, realizing closed-loop management from the implementation of diagnosis and treatment to prognostic management, and effectively ensuring that patients receive high-quality and continuous medical services. However, considering the resource differences and implementation difficulties in different medical environments, this indicator system still needs further verification and optimization in multi-center settings to enhance its universality and reliability. Looking forward, the research team suggests actively exploring the application potential of cutting-edge technologies such as artificial intelligence and big data analysis in the quality control of lung cancer diagnosis and treatment, using digital means to improve the efficiency and accuracy of evaluation. At the same time, with the iteration of diagnosis and treatment technologies and the evolution of clinical needs, the indicator system should be continuously updated dynamically to ensure that it always conforms to the development trend of the industry. Only in this way can we provide personalized and high-efficiency medical services for lung cancer patients, and promote the achievement of the ultimate goals of prolonging the survival cycle and improving the quality of life. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.